Cyberonics Incorporated

Cyberonics, Inc. (NASDAQ: CYBX) pioneered the Vagus Nerve Stimulation (VNS Therapy™) System. Founded in 1987 to design, develop and market implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders, Cyberonics has emerged as a leader in the neuromodulation industry. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve in the left side of the neck. This therapy has proven effective in significantly reducing the number and/or intensity of seizures in many people suffering from epilepsy and has the potential for use in the treatment of other inadequately treated, chronic disorders. In 1997, Cyberonics received approval from the Food and Drug Administration (FDA) to market VNS Therapy for the treatment of epilepsy. Since that time, more than 32,000 patients worldwide have been implanted with the device. These patients have accumulated in excess of 100,000 patient years of experience using this life-enhancing therapy. The remarkable success of VNS Therapy in the treatment of epilepsy has served as a platform for continued innovation. On July 15, 2005 , after seven years of extensive study and clinical trials, VNS Therapy was approved by the FDA as a long-term adjunctive treatment for treatment-resistant depression. It is also at various levels of study as a potential treatment for other chronic disorders, including anxiety, Alzheimer’s, bulimia, and migraine headaches. Headquartered in Houston , Texas , Cyberonics has additional offices in Brussels , Belgium . The Company markets the VNS Therapy system in selected markets worldwide.

Contact Details: The Cyberonics Building 100 Cyberonics Boulevard Houston TX 77058 United States of America Tel: 1 (888) 867-7846 Fax: (281) 218-9332 Email: WWW: www.cyberonics.com/

Loading...

Recent Publications by Cyberonics Incorporated:
Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Non-peptidic delta opioid receptor agonists are being evaluated for a wide...	21st February, 2007	Epilepsy Research Section, National Institute of Neurological Disorders	Pharmacol Biochem Behav. 2006 Oct;85(2):428-34. Epub 2006 Nov 15. DOI Direct Link
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. BACKGROUND: It is widely believed that most antidepressant medications...	27th April, 2005	Cyberonics, Houston, TX, USA.	J Psychiatr Res. 2005 Mar;39(2):161-72. DOI Direct Link
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. BACKGROUND: While emotional symptoms such as depressed mood and loss of...	13th April, 2005	Cyberonics, Houston, TX 77058, USA.	J Psychiatr Res. 2005 Jan;39(1):43-53. DOI Direct Link
Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. OBJECTIVE: To evaluate data supporting the ability of venlafaxine, an...	30th April, 2003	Clinical and Medical Affairs, Cyberonics, Houston, TX 77058, USA.	Acta Psychiatr Scand Suppl. 2002;(415):24-30.

BioNews Results for Cyberonics Incorporated:
News and FDA Updates for GLG Life Tech (NASDA:GLGL), PharMerica (NYSE:PMC), Cyberonics (Nasdaq:CYBX)	Los Angeles Chronicle:  Nov 21 2009 8:33PM Matching: cyberonics
Cyberonics Beats, Raises Outlook	FDA News:  Nov 20 2009 11:05PM Matching: cyberonics
Cyberonics Reports Record Sales and Operating Profit in Fiscal 2010 Second Quarter Increases Sales and Operating Income Guidance	Yahoo! Canada:  Nov 19 2009 2:57AM Matching: cyberonics
Cyberonics Reports Record Sales and Operating Profit in Fiscal 2010 Second Quarter	RBC Dain Rauscher:  Nov 18 2009 10:37PM Matching: cyberonics
Cyberonics Provides Update on Tax Position	SmartBrief:  Nov 17 2009 5:49AM Matching: cyberonics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Cyberonics Incorporated news.

Cyberonics Incorporated Clinical Trials:
Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures

Cyberonics Incorporated Patents:
US Patent No.	Title
4979511	Strain relief tether for implantable electrode
5251634	Helical nerve electrode
5263480	Treatment of eating disorders by nerve stimulation
5269303	Treatment of dementia by nerve stimulation
5299569	Treatment of neuropsychiatric disorders by nerve stimulation
→View more Cyberonics Incorporated patents.

Cyberonics Incorporated (CYBX) Financial information Links from Barchart
CYBX Quote from from Barchart.com
CYBX Chart from from Barchart.com
CYBX Profile from from Barchart.com
CYBX Opinion from from Barchart.com
→View more Cyberonics Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 942 times since April 2007, the link to the organisation's website has been followed 145 times

Search for more companies in Houston

Search for more companies in TX

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Cyberonics Incorporated